Final Program

262 TUESDAY • MAY 17
P620
Facilitator:
P621
P622
P623
P624
P625
P626
P627
C39
Access to Methacholine Challenges in Northern Alberta; A
Quality Assurance Project/M. Peters, D. Pawluski, E. James, D.
Stollery, E. Wong, D.W. Cockcroft, D. Vethanayagam, Edmonton,
Canada, p.A4967
S.B. Khatri, MD, MSc, Cleveland, OH
Phone Interventions Reduce ED Visits in Moderate Persistent
Asthma in a Resident Run Community Hospital/K. Gopalratnam,
A. Geeti, Y.A. Adjepong, M.J. Smith, D. Lindahl, Bridgeport, CT,
p.A4968
Patient Characteristics and Health Outcomes Among Patients
with Allergic Asthma Treated with Inhaled Corticosteroids and
Long-Acting Beta Agonists Combination Therapy/L.K. Lee, S.
Gabriel, E. Obi, B. Paknis, B.E. Chipps, Foster City, CA, p.A4969
Allergic Status Is Associated with Increased Number of
Asthma Exacerbations/W.J. Calhoun, T.A. Omachi, S.R. Reddy,
E. Chang, M.S. Broder, J. Antonova, Galveston, TX, p.A4970
Clinical Characteristics of Asthmatic Patients with Influenza-Like
Illness and Risk for Severe Exacerbations in Mexico/P.
Paulin-Prado, K. Nishimura, L. Freimanis-Hance, S. Hunsberger, J.
Beigel, A. Galindo-Fraga, A.A. Ortiz-Hernandez, B. Llamosas-Gallardo,
S. Moreno-Espinosa, R. Valdez-Vazquez, M. Magana-Aquino, G.M.
Ruiz-Palacios, A. Ramirez-Venegas, Mexico, Mexico, p.A4971
A Cluster Analysis of Bronchial Asthma Patients with
Depressive Symptoms/Y. Seino, N. Shimizu, I. Mashima, T.
Sakagami, T. Koya, F. Yoshimine, T. Hasegawa, Y. Muramatsu, K.
Muramatsu, E. Suzuki, T. Kikuchi, Niigata, Japan, p.A4972
Overuse of Antibiotics Among Patients Hospitalized for
Exacerbations of Asthma/P.K. Lindenauer, M.S. Stefan, L.C.
Feemster, M.-S. Shieh, S.S. Carson, D.H. Au, J.A. Krishnan,
Springfield, MA, p.A7878
Asthma Care Paths in Urban Settings: Identifying Local
Barriers to Care to Pilot Targeted Solutions/J. Chang, M. Latifi,
M. Ferrari, R. Engineer, S. Podolsky, S.B. Khatri, Cleveland, OH,
p.A7879
THEMATIC POSTER SESSION
IPF: MORE ON DIAGNOSIS AND THERAPY
9:00 a.m. - 4:15 p.m. MOSCONE CENTER
Viewing: Posters will be on display for entire session.
Area D, Hall D (North Building, Lower Level)
Discussion: 11:00-11:45: authors will be present for individual discussion
11:45-12:45: authors will be present for discussion with assigned facilitators
Facilitator:
P391
G. Raghu, MD, Seattle, WA
Using Hyperpolarized 129Xe Imaging to Quantify Apical Vs.
Basal and Central Vs. Peripheral Gas Exchange Impairment in
Idiopathic Pulmonary Fibrosis/J.M. Wang, S.H. Robertson, M.
He, R.S. Virgincar, G.M. Schrank, R.M. Smigla, T. O’Riordan, J.
Sundy, L. Ebner, C.R. Rackley, H.P. McAdams, B. Driehuys,
Durham, NC, p.A4973
P392
P393
P394
Quantitative Image Analysis of Spirometry-Guided HRCT in a
Phase 2 Study of PRM-151 in Patients with Idiopathic
Pulmonary Fibrosis/B. Van Den Blink, B. Bartholmai, J.R.
Miedema, C.J. Lammering, E.E. Van Der Wall, M.Y. Gerrits-Boeye,
M. Wapenaar, K.M. Carroll, R. Chamberlain, H.C. Hoogsteden, G.
Raghu, Rotterdam, Netherlands, p.A4974
The Changes and Clinical Significance of Serum Laminin, Type
IV Collagen, Type III Procollagen N-Terminal Peptide and
Hyaluronic Acid in Pulmonary Fibrosis Patients/Y. Su, D. Weng,
Shanghai, China, p.A4975
Care of Patients with IPF at a Community Hospital in the UK.
Adherence to National Institute for Health and Care Excellence
(NICE) Guidance and Implications for Network Care/S. Diver, S.
Paterson, T. Gatheral, Lancaster, United Kingdom, p.A4976
P395 Correlation Between Serum High-Mobility Group Box Protein 1
Level and Prognosis in Acute Exacerbation of Fibrosing
Interstitial Pneumonia/H. Shimizu, S. Sakamoto, K. Furuya, A.
Kinoshita, A. Suzuki, K. Koyama, N. Urabe, T. Isshiki, K. Gocho, G.
Sano, K. Sugino, K. Isobe, Y. Takai, S. Homma, Ootaku, Japan,
p.A4977
P396
P397
P398
P399
P400
P401
P402
P403
Assessing the Impact of Obstructive Sleep Apnea on Survival
in Idiopathic Pulmonary Fibrosis/K. Janssen, Q. Wang, D.
Perlman, R. Tomic, H. Kim, Minneapolis, MN, p.A4978
Cardiovascular Risk Factors, Comorbidities and Concomitant
Medications from Three Phase 3 Trials of Pirfenidone in
Idiopathic Pulmonary Fibrosis/M. Glassberg, S.D. Nathan, C.
Lew, K. Raimundo, B.-M. Day, J. Stauffer, W. Chou, P.W. Noble,
Miami, FL, p.A4979
Cardiovascular Events in Phase 3 Trials of Pirfenidone in
Idiopathic Pulmonary Fibrosis (IPF)/M. Glassberg, S.D. Nathan,
C.-Y. Lin, C. Lew, K. Raimundo, J. Stauffer, W. Chou, P.W. Noble,
Miami, FL, p.A4980
Prevalence of Basilar Fibrosis on Abdominal Computerized
Tomography Imaging/G. Magda, J.L. Della-Santina, S.A.
Stayrook, N. Weir, C.S. King, S. Ahmad, O.A. Shlobin, A.W. Brown,
C.P. Della-Santina, S.D. Nathan, Washington, DC, p.A4981
FAM13A Polymorphism as a Prognostic Factor in Patients with
Idiopathic Pulmonary Fibrosis/C. Hirano, S. Ohshimo, Y. Horimasu,
H. Iwamoto, K. Fujitaka, H. Hamada, N. Hattori, F. Bonella, J. Guzman,
U. Costabel, N. Kohno, Hiroshima, Japan, p.A4982
The Importance of Longitudinal Micro-CT-Derived Biomarker
Quantification for Therapy Evaluation in Mouse Models of
Lung Fibrosis/G. Vande Velde, E. De Langhe, J. Poelmans, A.
Hillen, U. Himmelreich, J. Vanoirbeek, R. Lories, Leuven, Belgium,
p.A4983
The Usefulness of Direct Hemoperfusion with Polymyxin
B-Immobilized Fiber (PMX-DHP) Treatment on Acute
Exacerbation of Interstitial Pneumonitis/H. Furusawa, M.
Sugiura, Y. Miyazaki, N. Inase, Tokyo, Japan, p.A4984
Clinical Significance of Thyroid Antibodies and Hormones in
Patients with Idiopathic Interstitial Pneumonia/Y. Sato, Y.
Tanino, T. Nikaido, K. Misa, R. Togawa, Y. Suzuki, M. Uematsu, A.
Fukuhara, S. Sato, J. Saito, X. Wang, M. Munakata, Fukushima,
Japan, p.A4985
ATS 2016 • San Francisco